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filament protein myosin (Spudich 2001). The myosin fam-
ily of proteins consists of more than two dozen distinct 
members (Ferenczi 2000; Pfitzer 2001). Myosin mole-
cules are large (with a size of about 500 kDa), actin-bind-
ing ATPases, which act as molecular motors to provide a 
variety of movement-associated functions (Hartman and 
Spudich 2012; Spudich 2001; Syamaladevi et al. 2012). 
The 440-kDa Myosin II dimer, arranged into bipolar fila-
ments, also known as thick filaments and containing 294 
molecules (Atkinson and Stewart 1991), are the molecular 
motors responsible for muscle contraction. Myosin is the 
mechanochemical energy transducer, whose motor domain 
(or head) interacts with actin in the thin filament generat-
ing force, power, and shortening (Irving et al. 1992). Each 
myosin molecule is a hexameric protein containing two 
heavy chains (MHC) and four light chains. The stability 
of the α-helical neck region of the S1 subfragment of each 
myosin heavy chain, also known as the lever arm region, 
is stabilized by two small light-chain proteins known as 
MYL1 (the alkali light chain, or the essential light chain, 
ELC, ~25 kDa) and MYL2 (the regulatory light chain or 
RLC, ~19 kDa) (Fig. 1). Both RLC and ELC have a struc-
ture closely related to that of the EF hand calcium binding 
protein family such as troponin C and calmodulin (Weeds 
1969). However, unlike other EF hand proteins, RLC has 
only one Ca2+/Mg2+ binding EF hand domain between 
amino acids 37 and 48 (Collins 1976; Rayment et al. 1993). 
Thus, modulation of contraction by RLC phosphorylation 
has attracted much interest.
In striated muscles, activation of the myosin motor is 
mediated by thin-filament activation upon Ca2+ binding 
(on/off) to the actin–troponin–tropomyosin complex, not 
by RLC phosphorylation. RLC phosphorylation acts as a 
modulator and not as a switch in striated muscle (Sweeney 
et al. 1993; Szczesna 2003). In striated muscle, the RLC 
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phosphorylation state may function as the molecular mem-
ory of recent activation and contractile events by altering 
actomyosin interactions after repeated muscle activation 
(Kamm and Stull 2011; Matsumura et al. 2001; Scruggs 
and Solaro 2011). It has been proposed that phosphoryla-
tion induces movement of the myosin head away from 
the thick filament backbone toward the thin filament, thus 
increasing the probability of myosin attachment to actin 
(Colson et al. 2010; Levine et al. 1996). Below we describe 
the structure of RLC, the phosphorylation sites, and their 
functional significance.
Structure, isoforms, phosphorylation sites, 
and function of RLC
Structure
RLC (~19 kDa) is a member of the EF-hand superfam-
ily (which is a helix-loop-helix structural domain or motif 
found in a large family of calcium-binding proteins). The 
N-terminal domain is similar in structure to calmodulin. 
RLC is non-covalently bound to the C-terminus of myosin 
S1 subfragment (Fig. 1b). The N-terminal domain of 
RLC wraps around the region between amino acids Asn 
825 and Leu 842 at the C-terminal end of myosin S1. The 
C-terminal domain of RLC binds in the region between 
Glu 808 and Val 826 of myosin S1 (Rayment et al. 1993). 
The number of phosphorylatable serines of RLC differs 
between species and between tissues indicative of the 
presence of unique tissue-specific isoforms and phospho-
variants, thus providing scope for a variety of functions. 
Although the isoforms of RLC are similar in structure, in 
particular in the divalent cation-binding sites and proxi-
mal phosphorylatable serines in both smooth and striated 
muscles, they have relatively low sequence similarity 
(~57 %), suggesting functional differentiation (Scruggs 
and Solaro 2011).
Isoforms
Within the same tissue, there are multiple isoforms of RLC. 
In adult human skeletal muscle, there are three major RLC 
isoforms: two fast isoforms, namely type I (NCBI Acces-
sion # P24732) and type II (NCBI Accession # P02608), 
and one slow isoform (NCBI Accession # P10916, same as 
Fig. 1  RLC structure. a Chicken skeletal muscle isoform of RLC 
crystal structure with the helix-loop-helix showing four EF hands 
separated by loops (left). The N- and the C-termini are shown (PDB 
ID # 2MYS; (Rayment et al. 1993) that wrap around the C-terminus 
side of the chicken skeletal myosin S1 sub-fragment (right) (Ray-
ment et al. 1993). The N-terminal amino acids 1-20 are missing from 
the crystal structure due to its flexibility (inherent disorder). The 
myosin head is the motor domain of the myosin molecule, the site 
of actin binding and contains the ATP hydrolysis pocket. The regu-
latory (RLC) and essential (ELC) light chains wrap around the lever 
arm conferring rigidity and stability to this long alpha-helical rod. b 
A simplified pictorial representation of the acto-myosin structure 
with RLC. The diagram shows the thick (myosin containing, red) 
filament backbone and thin (actin containing, white circles represent 
actin monomers) filament with an acto-myosin cross-bridge. The 
ELC (yellow box) and phosphorylated RLC (blue box) are in the neck 
region of the myosin heavy-chain monomer. The myosin head inter-
acts weakly or strongly with the thin filament forming a cross-bridge 
structure. The Troponin complex (purple oval) on the thin filament 
comprising of troponin C, troponin I, and troponin T activate muscle 
contraction via calcium binding. Myosin binding protein C (MyBP-
C) (cyan) is associated with the thick filament backbone and also 
interacts with the thin filament (not drawn to scale). (Figure is modi-
fied from Fig. 6c of Farman et al. 2009)
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ventricular RLC), where fast and slow describe the physi-
ological behavior of different muscle groups. These three 
isoforms are encoded by different genes in the human chro-
mosome 16, but with a high degree of sequence homology 
(Szczesna 2003).
In human heart, there are two different RLC isoforms 
expressed from separate genes, namely the atrial iso-
form (MYL2a) (NCBI Accession # M94547) encoded 
from a gene in chromosome 7 and the ventricular iso-
form (MYL2v) (NCBI Accession # P10916) encoded 
from a gene in chromosome 12, with the ventricular 
ones expressed in both ventricular myocardium and slow 
twitch skeletal muscle (MYL2f) (Kubalak et al. 1994; 




Vertebrate skeletal muscle RLC is phosphorylated at two 
serine (Ser) residues, Ser14 and Ser15 (Fig. 2), by a skel-
etal muscle-specific Ca2+/calmodulin-dependent myosin 
light-chain kinase (skMLCK) (Blumenthal and Stull 1980). 
The specific roles of the two neighboring RLC phosphoryl-
ation sites are unknown, but RLC phosphorylation at either 
site has a profound effect on force potentiation (isometric 
twitch tension potentiation) in fast, but not in slow, skeletal 
muscle (Moore and Stull 1984). Tarantula muscle has very 
thick myosin filaments, and their structure has been well 
studied by electron microscopy. It has been found that RLC 
Fig. 2  Multiple sequence alignment (MSA) of different RLC iso-
forms from different laboratory model organisms and humans show-
ing eight conserved predicted helices (red) forming part of the con-
served four EF-hand secondary structure. The helix-loop prediction 
was performed in the Ali2D Bioinformatics toolkit of the Max Plank 
Institute of Developmental Biology (http://toolkit.tuebingen.mpg.de/
ali2d). The degree of confidence in prediction secondary structure is 
color coded in shades of increasing color intensity indicating increas-
ing prediction confidence (for helix (H): white to dark red, for loops 
(E): white to dark blue). The black arrows indicate the conserved 
sites of physiologically relevant phosphorylation sites of RLC across 
species and tissues. The asterisks (*) indicate conserved residues 
across the sequences in the MSA. Sequences were retrieved from 
NCBI. Abbreviations used for biological sources of RLC sequences 
with their respective gene names and NCBI protein accession num-
bers are as follows: DrosoIFM (Drosophila indirect flight muscle, 
MLC2, P18432.2), HSmooth (human smooth muscle, MYL12B, 
O14950.2), RatSmooth (rat smooth muscle, MYL12B, P18666.3), 
MSmooth (Mouse smooth muscle, MYL12B, Q3THE2.2), ChS-
mooth (chicken smooth muscle, MYL12A, P24032.2), HAtr (human 
atrial muscle, MYL7, Q01449.1), RatAtr (rat atrial muscle, MYL7, 
NP_001099487.1), MAtr (mouse atrial muscle, MYL7, Q9QVP4.1), 
HSlowSkel (human slow skeletal muscle, same as human ventricu-
lar), HVentr (human ventricular muscle, MYL2, P10916.3), MVentr 
(mouse ventricular muscle, MYL2, P51667.3), RatVentr (rat ven-
tricular muscle, MYL2, P08733.2), ChFastSkel (chicken fast skeletal 
muscle, MYLPF, P02609.2), HFastSkel (human fast skeletal mus-
cle, MYLPF, Q96A32.1), MFastSkel (mouse fast skeletal muscle, 
MYLPF, P97457.3) RabastFSkelII (rabbit fast skeletal type II muscle, 
MYLPF, P02608.3), RatFastSkel (rat fast skeletal muscle, MYLPF, 
P04466.2)
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phosphorylation changes the orientation of the myosin 
head on the thick filament backbone and is the contractile 
basis of force potentiation in striated muscles. It was found 
that force potentiation occurs by sequential and coopera-
tive phosphorylation of two RLC sites in tarantula thick 
filament: first Ser35 by Protein Kinase C (PKC) and then 
Ser45 by Myosin Light Chain Kinase (MLCK) (Espinoza-
Fonseca et al. 2015). This is further validated by molecular 
dynamic simulations showing that the diphosphorylation 
of both tarantula smooth and striated muscle stiffens the 
N-terminal extension of RLC (region where phosphoryla-
tion occurs) so as to prevent its docking back towards the 
myosin S1 region, and in this way helps the free myosin 
head with Ser35 phosphorylation to remain away from 
thick filament backbone and available for actin binding 
(Alamo et al. 2015). It must, however, be borne in mind that 
tarantula thick filament may function very differently from 
vertebrate thick filaments. However, electron microscopic 
analyses of rabbit skeletal muscle showed that RLC phos-
phorylation has a major role in structural transitions, and 
modifies the mobility and disorder of the myosin head and 
myosin head crown/helical arrangement in the thick fila-
ment backbone resulting in force potentiation (Levine et al. 
1996). RLC phosphorylation-induced force potentiation is 
enhanced in both disease (muscular dystrophy) and aging, 
both of which affect neuro-muscular coupling (Smith et al. 
2010). In these disorders, RLC phosphorylation may be a 
compensatory mechanism enhancing force potentiation. 
These effects and their physiological relevance may stem 
from RLC phosphorylation-induced movement of myo-
sin heads away from the thick filament backbone towards 
the thin filament target zones facilitating contraction (see 
Fig. 3). 
Mammalian cardiac muscle
In striated cardiac muscle from mouse or rat, RLC exists 
in three states: unphosphorylated, singly phosphorylated 
at serine 14 or 15, and doubly phosphorylated at serine 14 
and 15. These sites are mostly phosphorylated by a cardiac-
specific MLCK (cMLCK), and partly by zipper-interacting 
kinases (ZIP Kinase). While mouse and rat possesses phos-
phorylatable sites at both Ser14 and Ser15, human cardiac 
RLC (cRLC) has only one single phosphorylatable site 
at Ser15 (Fig. 2) (Lyon et al. 2009; Scruggs et al. 2010). 
Interestingly, human cRLC contains asparagine (Asn) 
instead of Ser14. Asn14 can be deamidated to aspartic acid 
(Pasparakis et al. 2010), chemically mimicking the nega-
tively charged state of a phosphorylated serine, although 
there is no evidence that Asn14 is indeed deamidated 
Fig. 3  Graphical representation of the effect of RLC phosphorylation 
on myosin head and lever arm arrangement. (Figure modified from 
Fig. 6c of Farman et al. 2009) Model based on skeletal muscle (Dug-
gal et al. 2014; Midde et al. 2013) and cardiac muscle (Kampoura-
kis and Irving 2015). In this model, without RLC phosphorylation, 
the myosin S1 and RLC regions are in conformational equilibrium 
between lying/binding to the thick filament backbone surface (OFF 
state) and moving away towards thin filament (ON state) controlled 
by the RLC and the thick filament surface. This equilibrium is shifted 
towards the ON state upon RLC phosphorylation, possibly due to 
weakened electrostatic interaction between the added phosphate and 
negatively charged thick filament surface. The entire thick filament 
arrangement of myosin heads and other sarcomeric proteins (MyBP-
C, Troponin complex etc.) are not shown for simplicity. Not drawn to 
scale. (Notes: The ON and OFF states mentioned here are not related 
to the activation/deactivation with calcium binding/unbinding to Tro-
ponin C. The OFF-state myosin heads without RLC phosphoryla-
tion is drawn here lying on the thick filament backbone in the same 
direction as in the ON state, but it is possible that the OFF-state heads 
may fold on the opposite direction interacting with the thick filament 
backbone as drawn previously in Fig. 5 of Kampourakis and Irving 
2015)
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physiologically. Therefore, human cRLC may exist in three 
distinct charged species in vivo: one unphosphorylated, 
one singly phosphorylated, and one phosphorylated/deami-
dated mimicking a doubly phosphorylated state (Scruggs 
et al. 2010). Moreover, isoform compositions expose dif-
ferences between species. For example, human cRLC has 
two distinct charged isovariants with identical molecular 
weights, with one being more highly expressed and highly 
phosphorylated (Morano 1992; van Der Velden et al. 2001). 
Moreover, in non-failing human heart, the α-MHC content 
comprise as much as 10 % of the total MHC in cardiac sar-
comeres (Miyata et al. 2000). This indicates that the iso-
enzymes in human cardiac muscle are not only created by 
the two different isovariants of RLC, but different MHC 
composition of the adult human left ventricle. In contrast, 
rat has one ventricular RLC isoform but the three isoen-
zymes are formed as mixtures of α and β MHC (Kumar 
et al. 1986). Phosphorylation of RLC enhances the affinity 
of cross-bridges for action, or the rate of cross-bridge entry 
into the force generating states by moving cross-bridges 
closer to the thin filament (Colson et al. 2010). Physiologi-
cally, RLC phosphorylation may enhance the calcium sen-
sitivity of cardiac myofilaments (Morano et al. 1985). Chris 
Toepfer sees an effect of phosphorylation in rat cardiac tra-
beculae at saturating calcium, so the effect cannot be fully 
attributed to enhancement of calcium sensitivity (Toepfer 
et al. 2013). Engineered in vivo mutations highlight the 
role of Ser14 and Ser15 phosphorylation (Ding et al. 2010; 
Sanbe et al. 1999). Phosphorylation of cRLC at both sites 
is required for normal cardiac ejection dynamics at baseline 
and also following β1-adrenergic stimulation. Genetic engi-
neering of the phosphorylation sites showed that Ser15 of 
cRLC is specifically phosphorylated by cMLCK (Kampou-
rakis and Irving 2015), confirming that Ser15 is a physi-
ologically relevant site.
Mammalian smooth muscle
In contrast to striated muscle, smooth muscle is activated 
by RLC phosphorylation at Ser19 of RLC. Both Thr18 
and Ser19 are phosphorylated by smooth muscle specific 
myosin light chain kinase (smMLCK) in the presence of 
calcium and calmodulin (Pearson et al. 1984). Smooth 
muscle activation is, however, more complex than merely 
being turned on by phosphorylation of RLC and turned off 
by dephosphorylation. Smooth muscle force generation 
is maintained over long periods of time even though the 
extent of RLC phosphorylation declines over time (Driska 
et al. 1981). In vitro, smooth muscle RLC can be simulta-
neously phosphorylated at Thr18 position along with Ser19 
by integrin-linked kinases and zipper-interacting kinases 
(ZIPK) (Ihara and MacDonald 2007; Wilson et al. 2005). 
Di-phosphorylation may occur in diseases of smooth 
muscle (Walsh 2011). Compared with mono-phosphoryla-
tion exclusively at Ser19, di-phosphorylation at both Ser19 
and Thr18 slows relaxation of arterial smooth muscle by 
reducing the rate of dephosphorylation of the RLC (Suther-
land and Walsh 2012). Using Mn2+-phos-tag gel electro-
phoresis technology for detecting phosphorylated vari-
ants of proteins, Aguilar et al. showed three differentially 
charged species of RLC in cultured uterine smooth muscle 
myocyte: unphosphorylated, singly and doubly phospho-
rylated (Aguilar et al. 2011). In spite of finding di-phos-
phorylated RLC in smooth muscle, mono-phosphorylated 
RLC at Ser19 by Ca2+/calmodulin-dependent smMLCK 
predominates physiologically in adult smooth muscle tis-
sues. In vitro, other phosphorylatable sites of RLC in 
smooth muscle are found. Calcium-activated phospholipid-
dependent protein kinase C (PKC) phosphorylates Ser1, 
Ser2, and Thr9 of smRLC, which reverses the increase in 
ATPase activity associated with smMLCK phosphorylation 
at Ser19 (Bengur et al. 1987; Ikebe et al. 1987).
What do we know about the role of RLC 
phosphorylation?
Skeletal muscle
Unlike in smooth muscle, RLC phosphorylation does not 
act as an activation switch but modulates striated muscle 
contraction. However, as in smooth muscle, RLC phos-
phorylation in skeletal muscle may also contribute to the 
release of the inhibition due to head–head and head–thick 
filament backbone interactions, facilitating binding with 
actin (Craig et al. 1987; Zhao et al. 2009). However, this 
role is not well understood. RLC phosphorylation enhances 
actomyosin interactions to accelerate myosin ATPase 
kinetics and force generation following calcium activa-
tion in skeletal muscle (Sweeney and Stull 1990). This is 
supported by structural studies which show that phospho-
rylation promotes the movement of the myosin heads away 
from the thick filament backbone resulting in the rotation 
of the cross-bridge/lever arm (Fig. 3) (Irving et al. 2000; 
Ushakov et al. 2011). In skeletal muscle, RLC phospho-
rylation may affect stiffness of the lever arm under iso-
metric conditions and may be bringing the cross-bridges 
closer to the thin filament, without an effect on isometric 
tension generation. However, in non-isometric conditions, 
in vitro motility assays showed that actin filament gliding 
slows down upon RLC phosphorylation due to an increase 
in the myosin duty cycle (Greenberg et al. 2009). However, 
the structure of the myosin molecule or filament bound to 
a glass substrate as used in gliding assays may be substan-
tially different from that encountered in muscle, which may 
result in different effects of phosphorylation in these two 
types of experiments.
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Effect of RLC phosphorylation on actomyosin ATPase
Myosin ATPase activity, in the absence of actin, is not 
affected by RLC phosphorylation (Persechini and Stull 
1984). In fibers, phosphorylation of RLC enhances Ca2+ 
sensitivity of force development, but only slightly acceler-
ated ATPase activity in skeletal muscle with low statistical 
significance in both reconstituted myosins and in permeabi-
lized muscle fibers (Szczesna et al. 2002).
Effect of RLC phosphorylation on force development 
and shortening
Using rabbit psoas muscle fibers, it was found that RLC 
phosphorylation slowed muscle shortening velocity by 
~40 % under physiological fatigue condition (such as 
30 °C, low pH, and increased Pi concentration) of muscle 
(Karatzaferi et al. 2008), independent of myosin and in 
both relatively lower and higher temperatures. It has been 
proposed that at higher temperature in fatigued muscle with 
phosphorylated RLC, the myosin heads bind to the thick 
filament backbone, forming ordered arrays. This bind-
ing results in the myosin heads being further away from 
the thin filament binding sites upon Ca2+ activation, and 
increasing the fraction of myosin heads in non-force gen-
erating states during extreme fatigue conditions. Albeit, 
it is not known if inhibition of shortening velocity during 
fatigue is due to the direct role of RLC phosphorylation on 
nucleotide binding to myosin motor domain or not.
Interestingly, recently it was found that in a skeletal 
myosin light chain kinase knock-out (skMLCK−/−) 
mouse, the extensor digitorum longus (EDL) muscle 
exhibits no post-tetanic force potentiation after potenti-
ating stimuli compared to that in wild-type control mice 
(Gittings et al. 2016). This observation highlights the link 
between RLC phosphorylation in force potentiation as 
without skMLCK, the majority of skRLC would remain 
non-phosphorylated.
Cardiac muscle modulation by RLC phosphorylation
The proportion of cardiomyocytes with well-organized 
sarcomeric structure increased in vitro in cells containing 
phosphorylated RLC compared to unphosphorylated cells 
in rat and zebra fish (Aoki et al. 2000; Seguchi et al. 2007). 
This indicated that RLC phosphorylation is involved during 
the development of cardiac sarcomeres. Some studies do 
not show a role for RLC phosphorylation; for example, it 
was shown that cardiac performance can be increased with-
out increasing RLC phosphorylation in mice (Chang et al. 
2013). Increased performance may be achieved by activat-
ing other signaling pathways such as CaMKII and with 
the help of neuregulin. However, RLC phosphorylation 
facilitates force production by increasing maximal iso-
metric tension, calcium sensitivity of force, and the rate of 
force redevelopment at intermediate and saturating calcium 
activation levels (Olsson et al. 2004; Szczesna et al. 2002). 
Overall, RLC phosphorylation facilitates actomyosin inter-
action, most likely accelerates actomyosin kinetics, and 
enhances power output in cardiac muscle. These functional 
enhancements may promote sarcomeric organization dur-
ing development. X-ray diffraction experiments on car-
diac trabeculae with in situ RLC phosphorylation suggests 
a movement of the myosin head towards the thin filament 
upon phosphorylation (Colson et al. 2010), which might 
increase the probability of acto-myosin cross-bridge forma-
tion (Scruggs and Solaro 2011).
Some of the familial hypertrophic cardiomyopathy 
(FHC) mutations known in human cardiac RLC are found 
in the region of the Ser15 phosphorylation site, affect 
RLC phosphorylation and have a physiological effect 
(Szczesna et al. 2001). In Szczesna et al.’s report, of par-
ticular relevance, was the decrease in RLC phosphoryla-
tion in the A13T (site close to Ser15 site) and R58Q (site 
far from Ser15 site) mutations causing abnormal α-helical 
content and reduced Ca2+-binding properties of RLC, 
which were compensated upon subsequent phosphoryla-
tion (Szczesna et al. 2001, 2002). This indicates that RLC 
phosphorylation may be a key compensatory mechanism 
to attenuate the physiological consequences of FHC muta-
tions in the heart. Toepfer et al. found that enrichment of 
RLC phosphorylation enhances force and power output in 
rat cardiac trabecular muscle (Toepfer et al. 2013). This 
study also shows that in both rats and humans, RLC phos-
phorylation increases with the severity of heart failure. 
This may support the view that RLC phosphorylation is 
a compensatory mechanism in cardiac disease. During the 
power stroke, the cross-bridge converts the torque gener-
ated in the myosin monomer into a linear displacement of 
the filaments with respect to each other (Burghardt and 
Sikkink 2013). Therefore, the possible immediate effect 
of RLC phosphorylation could be the movement of the 
myosin motor to facilitate inter-filament interactions, tran-
sient cross-bridge formation and detachment, and muscle 
contraction. Stelzer et al. incorporated MLCK to increase 
RLC phosphorylation in a MLCK knock-down back-
ground in permeabilized murine myocardium and found 
increases in the amplitude and rate of force development 
during stretch, i.e., enhancement of the stretch activation 
response. This further indicates that RLC phosphoryla-
tion increases force and power output in vivo, at least in 
the murine myocardium, by possibly increasing the rate 
of acto-myosin cross-bridge recruitment. Further work is 
required to understand the role of RLC phosphorylation 
on actomyosin kinetics, on stretch-activation, and on the 
behavior of the whole heart.
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The phosphorylation state of other myofibrillar proteins 
in both thick and thin filaments, namely that of myosin 
binding protein C (MyBP-C) and troponin I (TnI), are also 
affected by in vivo mutations of cRLC phosphorylation 
sites (Scruggs et al. 2009). There is evidence that MyBP-C 
binds to the myosin S2 region and RLC (Kampourakis and 
Irving 2015; Ratti et al. 2011). This indicates that cRLC 
phosphorylation events are linked to phosphorylation of 
other sarcomeric proteins. Signaling pathways may not 
control the phosphorylation of single proteins: the physi-
ological response to stimuli may be a balanced increase in 
phosphorylation of a number of target sites.
In the heart, the overall pattern of contraction depends 
on a spatial gradient of RLC phosphorylation that is closely 
related to cardiac torsion (Davis et al. 2002), the conse-
quence of which is an increased ejection fraction and car-
diac stretch activation response (Davis et al. 2001). It was 
proposed that this variation of RLC phosphorylation rang-
ing from high levels in the epicardium to low levels in the 
endocardium could be due to phosphatase activity that may 
be higher in the inner layers of the myocardium. This, in 
turn, could possibly be a mechanism to reduce inner wall 
stress of the heart during systole (Cohen 2002; Rajashree 
et al. 2005). These studies suggest that the gradient of RLC 
phosphorylation supports the cardiac torsional movement 
and thus facilitates overall cardiac contraction. Interest-
ingly, a recent study in rat heart shows that an increase in 
RLC phosphorylation slows down the rates of both cross-
bridge MgADP release and MgATP binding at 1.9-µm 
sarcomere length, whereas only slows down cross-bridge 
MgATP binding at 2.2-µm sarcomere length with no effects 
on the rate of MgADP release (Pulcastro et al. 2016). This 
indicates that RLC phosphorylation has a differential role 
on cross-bridge kinetics depending on sarcomere length. 
This connects to and adds to the concept that RLC phos-
phorylation can vary across the heart from left to right 
ventricles and between fibers based on the local extent of 
mechanical loading and stretching to optimize normal car-
diac torsional movement and overall contraction.
Recently, cardiac RLC phosphorylation was found to 
directly control the movement of the myosin-RLC region 
and myosin S1-region from a position more parallel and 
towards the thick filament backbone to a position more 
perpendicular and away from the thick filament backbone, 
facilitating cross-bridge formation, enhancing myosin 
kinetics, and force production (Kampourakis and Irving 
2015). This suggests that RLC phosphorylation is a major 
modulator in releasing the myosin head–thick filament 
backbone interaction and inducing movement away from 
the backbone towards the thin filament. This mechanism 
agrees well with the hypothesis proposed for super-relaxed 
state (SRX) of myosin head in cardiac muscle (Hooijman 
et al. 2011) and for skeletal muscle (Stewart et al. 2010). 
This ordered “blocked” (lying on thick filament) arrange-
ment of the myosin heads across the thick filament sur-
face in SRX is modulated by phosphorylation of RLC and 
MyBP-C (Kensler et al. 2011; Levine et al. 1996). Support-
ing this, de-phosphorylation of RLC stabilizes the ordered 
array of myosin heads bound or lying on the thick filament 
surface away from thin filament, decreasing cardiac power 
output during SRX (Dias et al. 2006; Scruggs et al. 2009).
Smooth muscle: the role of RLC phosphorylation
The role of RLC and its phosphorylation is better character-
ized in smooth muscle and non-muscle cells than in striated 
muscle. RLC phosphorylation triggers smooth muscle con-
traction, unlike in striated muscle. Phosphorylation of RLC 
in both smooth muscle and non-muscle myosins modulates 
the tension and activates the myosin ATPase (Bresnick 
1999). The mechanism by which RLC phosphorylation 
induces the release of the two-head interactions, a feature 
specific to smooth muscle to activate the myosin motor is 
not clearly known. According to molecular dynamics (MD) 
simulation along with electron paramagnetic resonance 
(EPR) and fluorescence resonance energy transfer (FRET) 
experiments, the smooth muscle RLC (smRLC) phospho-
rylation domain (PD) shifts to a more ordered state from 
a disordered conformation upon phosphorylation at Ser19 
(Espinoza-Fonseca et al. 2007). The overall tertiary struc-
ture of the RLC and the light chain domain region of the 
myosin S1 undergo a shift from a closed or ordered state 
to a more open or disordered state of conformation (Col-
son et al. 2012; Taylor et al. 2014) upon phosphorylation. 
This conformational change could facilitate the release of 
the myosin S1, activating its ATPase activity. In addition, in 
non-muscle cells as well, RLC phosphorylation is required 
for normal cell division processes and cytokinesis. Both 
the phosphorylation sites and the pattern of phosphoryla-
tion characterize striated and smooth muscle RLC phos-
phorylation and highlight the fact that the consequence of 
RLC phosphorylation is quite different in these two muscle 
classes.
Possible mechanism of RLC phosphorylation in striated 
muscle
The structural and functional role of RLC phosphoryla-
tion has also been investigated in genetic models such as 
Drosophila. X-ray diffraction on live flies and active mus-
cle fibers shows that RLC phosphorylation orients the 
myosin motor domain towards the thin filament target to 
enhance actin binding compared to non-phosphorylated 
RLC (Farman et al. 2009). Cross-bridges without RLC 
phosphorylation are more ordered in relaxed mammalian 
skeletal muscle since they lie closer to the thick filament 
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core (Cooke 2011). However, during contraction, skeletal 
muscle cross-bridges with phosphorylated RLC rotate at 
higher azimuthal angles and are less ordered compared to 
those without RLC phosphorylation (Midde et al. 2013). 
This is in contrast to what is found in insect flight muscle 
(Farman et al. 2009) where RLC phosphorylation reduces 
the azimuthal movement of the myosin head, enabling a 
better orientation towards actin targets. Moreover, in active 
isometric condition, Midde et al. (2013) found that rota-
tional movement of the myosin lever arm (myosin S1’s 
RLC region) is faster with phosphorylated RLC than with 
dephosphorylated RLC even with the myosin duty cycle 
and isometric tension remaining the same in both cases. 
Upon RLC phosphorylation, the myosin S1 head domain 
and the S1 RLC region are more disordered compared to 
non-phosphorylated RLC. However, Duggal et al. reported 
that in skeletal muscle, RLC phosphorylation has a mini-
mal effect on the ordering of the myosin S1 head domains 
or their distribution (Duggal et al. 2014). These contrasting 
results highlight the need for a better understanding of the 
role of RLC phosphorylation and that RLC phosphoryla-
tion may have different consequence in different tissues or 
animal systems. In summary, RLC phosphorylation causes 
disordering of the myosin head domain but not the RLC-
region of S1. The S1 RLC region may remain ordered due 
to its interaction with the thick filament backbone. Phos-
phorylation may shift this structural equilibrium possibly 
due to the electrostatic repulsion of phosphate with the 
negatively charged surface of the thick filament backbone. 
Alternatively, whether the effect of RLC phosphorylation 
is to disorder the S1’s RLC-region and S1’s myosin head 
domain or to just shift the equilibrium of the interaction 
between S1’s RLC region and thick filament backbone sur-
face to an “ON” state (not referring to calcium activation) 
may depend on the type of muscle skeletal (Midde et al. 
2013), or cardiac (Kampourakis and Irving 2015). In the 
ON-state, it is proposed that due to RLC phosphorylation, 
the myosin head and S1-RLC region axis is more perpen-
dicular to the thick filament backbone, whereas without 
phosphorylation in the OFF-state, it is more parallel to the 
thick filament axis (Kampourakis and Irving 2015) (see 
Fig. 3). RLC phosphorylation releases the inhibition (OFF 
state) caused by interaction between myosin S1 head–head 
and S1’s head domain/S1 RLC region with the thick fila-
ment backbone interaction to facilitate head and lever arm 
movement away from the backbone and towards the thin 
filament, based on evidence from smooth muscle (Bau-
mann et al. 2012; Rosenfeld et al. 1998), permeabilized 
mammalian cardiac muscle studies (Colson et al. 2010), 
and Drosophila indirect flight muscle (Farman et al. 2009). 
A summary of the known physiological functions of RLC 
phosphorylation in striated muscle is shown in Table 1.
Biomedical significance of RLC phosphorylation
As RLC phosphorylation modulates muscle cell behavior, 
defects in RLC phosphorylation result in dysfunction and 
disease. Mutations in either ELC or RLC are associated 
with myopathies in human heart and skeletal muscle (Poet-
ter et al. 1996).
In skeletal muscle, RLC phosphorylation plays a role 
in post-activation potentiation, which is induced by a sud-
den and intense voluntary contractile activity like jumping 
or sprinting etc. (Baudry and Duchateau 2007; Sale 2002). 
The role of RLC phosphorylation in post-activation poten-
tiation may stimulate research to improve human perfor-
mance in stretch (extrinsic) and endurance exercise. RLC 
phosphorylation and increased recruitment of motor units 
have been proposed as the mechanism of post-activation 
potentiation that leads to increased peak force and rate of 
force development during twitch contractions. Increas-
ing RLC phosphorylation may be an effective strategy for 
improving skeletal muscle performance in athletes as well 
as in the aging population.
In the heart, genetic knock-out mice were used to under-
stand the role of the ventricular and atrial isoforms of RLC, 
MYL2v, and MYL2a, respectively, in cardiac contractile 
function (Sheikh et al. 2015). The mutations of RLC are asso-
ciated with the mid left ventricular chamber hypertrophic car-
diomyopathy (HCM) phenotype. Although it is not entirely 
clear how these abnormal phenotypes are driven by changes 
at the molecular level, RLC mutants linked to these diseases 
are known to modify the cardiac myosin lever arm (Her-
nandez et al. 2007). Burghardt et al. studied the relationship 
between different disease-related mutants in RLC and heart 
diseases using photo-activatable GFP-tagged RLC (RLC-
PAGFP), a novel technique that permits single-molecule 
detection (Burghardt and Sikkink 2013). They found that 
the HCM-linked E134A mutation of RLC, a charged residue 
probably participating in the binding of human cardiac RLC 
to the myosin lever arm, affects actin binding during contrac-
tion evidenced by a decrease in isometric tension.
Cardiac hypertrophy is the heart’s response to a variety 
of extrinsic and intrinsic stimuli that impose increased bio-
mechanical stress (Frey and Olson 2003). Increased car-
diac RLC phosphorylation may limit cardiac hypertrophy 
by contributing to enhancement of contractile performance 
and efficiency. This may result from facilitating actomyosin 
interactions and enhancing contractility to adapt to cardiac 
stress (Huang et al. 2008; Muthu et al. 2012). Additionally, 
pressure overload leads to severe heart failure in mice with 
dephosphorylated cardiac RLC but less so in mice with 
over-phosphorylated cardiac RLC (Warren et al. 2012). 
Thus, strategies to control RLC phosphorylation may ben-
efit heart function in disease.
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In addition, measurement of the extent of RLC phospho-
rylation has potential as a diagnostic tool for human heart 
disease phenotypes. A recent study tested cardiac left ven-
tricular (LV) biopsy samples from patients either with LV 
hypertrophy and preserved systolic function or with LV 
dilation and reduced ejection fraction (Walker et al. 2013). 
In patients with preserved systolic function, cardiac RLC 
phosphorylation was unchanged relative to a control group 
of patients with normal LV function, whereas in patients 
with LV dilation and reduced ejection fraction, cardiac 
RLC phosphorylation was increased. A role for phospho-
rylation of RLC in various cellular functions and diseases 
is evident. Thus, understanding the stage-specific changes 
in phosphorylation of RLC in progressive heart diseases, 
either heart failure or cardiomyopathic conditions, may 
provide important and early diagnostic and therapeutic 
information.
In the paragraphs that follow, we will present a sum-
mary of existing methods for measuring and modifying the 
extent of RLC phosphorylation and discuss their merits and 
problems.
Techniques to phosphorylate or dephosphorylate 
RLC
Techniques to phosphorylate or dephosphorylate RLC 
include computational simulation, modeling, and experi-
mental methods. Mathematical simulations describe the 
phosphorylation and de-phosphorylation dynamics of 
RLC by modifying biochemical and enzymatic param-
eters (Kaneko-Kawano et al. 2012). However, simulations 
need validating by experimental data. Here, we emphasize 
experimental techniques for: (1) increasing phosphoryla-
tion of RLC, and (2) techniques to de-phosphorylate RLC, 
and (3) the measurement of phosphorylation levels. The 
merits and limitations of the experimental tools will be dis-
cussed, divided into in vivo and in vitro methods.
In vivo modifications
Much of our knowledge about native myosin light-chain 
functions comes from studies in muscle of animal mod-
els such as mouse, rat, rabbit, swine, zebrafish, and Dros-
ophila (Kaneko-Kawano et al. 2012). Several studies 
have measured the extent of native RLC phosphorylation 
in various tissues that seems to reflect variation in the 
phosphorylation extent between them. In quickly frozen 
biopsy samples of human heart, RLC phosphorylation 
varies between the atrial and the ventricular isoforms, 
with the two ventricular isoforms varying in the range of 
0.26–0.39 mol Pi/mol RLC (Morano 1999). Toepfer et al. 
(Toepfer et al. 2013) found a similar level of RLC phos-
phorylation (~0.4 mol Pi/mol RLC) at the inner ventricu-
lar wall of the human myocardium. However, basal RLC 
phosphorylation values found in different studies differ 
(Peng et al. 2014; Sanbe et al. 1999; Scruggs and Solaro 
2011). Heterogeneous levels of phosphorylation between 
different parts of the myocardium (Davis et al. 2001; 
Dias et al. 2006; Sheikh et al. 2012) add to the complica-
tion. For example, recently, the basal in vivo cRLC phos-
phorylation in the rodent heart is found to be even lower 
(<0.05 mol Pi/mol RLC) (Kampourakis and Irving 2015) 
than reported before (~0.4 mol Pi/mol RLC) (Toepfer et al. 
2013). The difference could also be caused by handling 
such as rapid dephosphorylation during sample prepara-
tion. Previously, in case of rodent models, RLC phospho-
rylation level in the inner left ventricular wall of rats hearts 
is found to be higher than in human (0.53 mol Pi/mol 
RLC) (Toepfer et al. 2013). However, normal RLC phos-
phorylation levels in swine left ventricular wall is similar 
to that in humans (Toepfer et al. 2013). In case of skel-
etal muscle, the extent of normal RLC phosphorylation is 
lower than in cardiac muscle, with the mouse fast twitch 
EDL muscles showing about 0.1–0.2 mol Pi/mol RLC, 
and the mouse slow twitch soleus muscle showing about 
0.08–0.18 mol Pi/mol RLC (Ryder et al. 2007). Therefore, 
in vivo modification of RLC phosphorylation status may 
result in directly measurable physiological effects.
Transgenic approaches: modulation by kinases
Transgenic techniques are widely used for in vivo modi-
fication, most of which are used to lower the RLC phos-
phorylation level. For this purpose, modulation of MLCK 
expression is frequently used. Mammalian smooth, skel-
etal, and cardiac muscle MLCKs are encoded by MYLK1, 
MYLK2, and MYLK3 genes, respectively (Gallagher et al. 
1991; Herring et al. 2000; Yin et al. 2006; Zhi et al. 2005). 
Ding et al. generated a transgenic mouse expressing the 
cMLCK hypomorphic allele (cMLCKneo/neo) by crossing 
cMLCK+/neo to each other in order to assess myosin RLC 
phosphorylation and cardiac performance in vivo (Ding 
et al. 2010). Two cMLCK-targeted embryonic stem cell 
clones were identified and injected into C57BL/6 blasto-
cysts that were transferred to the uterus of pseudo pregnant 
females. The extent of RLC phosphorylation in ventricular 
and atrial tissues of cMLCK+/neo mice was less than 5 %, 
indicating successful dephosphorylation by modulating 
MLCK. In another in vivo study, skMLCK-deficient mice 
were generated by transferring MYLK2 knock down into 
C57BL/B6 blastocysts and implanting into pseudopreg-
nant C57ICR females (Zhi et al. 2005). Loss of skMLCK 
reduced RLC phosphorylation in skeletal muscle by 95 % 
but had no effect on cRLC phosphorylation.
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It has been shown in smooth muscle that when tamox-
ifen treatment is combined with transgenic specific pro-
moter targeting and tamoxifen-activated Cre recombinase 
(a tyrosine recombinase enzyme derived from the P1 Bac-
teriophage), smMLCK expression is tissue-specifically 
abolished (Kuhbandner et al. 2000). This resulted in lower 
levels of RLC phosphorylation and consequent func-
tional implications (He et al. 2008). A similar strategy 
using tamoxifen activated and tissue-specific knock-out of 
smMLCK in vivo created a transgenic mouse strain with 
very low levels of RLC phosphorylation in smooth muscle 
(Somlyo et al. 2004; Zhang et al. 2010). This transgenic 
strategy could be applied in striated muscle as well. Thus, 
targeting MLCK genetically or in combination with phar-
macological intervention is effective for tissue-specific 
modulation of RLC phosphorylation. In vivo modifica-
tion of MLCK is an effective technique for examining the 
function of RLC phosphorylation in specific muscle tissue 
systems.
Transgenic approaches: P‑element‑mediated germline 
transformation
In vivo transgenic approaches were utilized in Drosophila 
to understand the role of the conserved MLCK phosphoryl-
ation sites of RLC in the stretch activation response, which 
has features resembling the behavior of mammalian cardiac 
muscle (Dickinson et al. 1997; Farman et al. 2009; Miller 
et al. 2011; Tohtong et al. 1995). Transposon-element or 
P-element-mediated germ-line transformation was used for 
creating transgenic Drosophila strains expressing mutant 
RLC with alanine substitutions of MLCK phosphorylat-
able serines (Ser66 and Ser67 of Drosophila RLC: Fig. 2) 
(Farman et al. 2009). Analysis of the mechanical response 
of permeabilized Drosophila flight muscles to applied sinu-
soidal length changes suggested that MLCK phosphoryla-
tion of the two conserved serines are required for normal 
orientation of the myosin heads towards actin target zones. 
This, in turn, accelerated myosin kinetics, increasing the 
number of strongly bound cross-bridges and stretch-acti-
vated power output (Miller et al. 2011).
Transgenic approaches: pseudo‑phosphorylation
Pseudo-phosphorylation is used both in vitro and in vivo. In 
this method, one or more amino acid residues are mutated 
to an acidic amino acid [aspartic acid (D) or glutamic 
acid (E)], which carries a negative charge that mimics the 
charged state of a phosphorylated residue. Based on the 
known cRLC crystal structure and on molecular dynam-
ics (MD) simulations, the in vivo phosphorylatable site of 
Ser15 is proximal to the D166V (Aspartate166 → Valine) 
mutation site of cRLC known to cause familial 
hypertrophic cardiomyopathy (FHC). Muthu et al. created a 
S15D (phosphorylated Ser15) pseudophosphorylated muta-
tion site in the cRLC protein carrying the D166V mutation 
(Muthu et al. 2014). They found that this in vitro strategy 
rescues the charged state of the aspartic acid (D166) site 
and the contractile function in vitro since the Ser15 and 
D166 sites are proximal. Recent in vivo research engi-
neered pseudophosphorylated RLC mice by using S15D-
D166V mutation technique (Yuan et al. 2015) and found 
that pseudophosphorylated RLC in the hearts of HCM mice 
is sufficient to prevent the development of the pathologi-
cal HCM phenotype. This method can also be used in other 
types of muscle. A similar strategy of combining MD simu-
lations and pseudophosphorylation has also been utilized in 
smooth muscle RLC to understand the structural effect of 
the physiological phosphorylation of Ser19 and the neigh-
boring Thr18 (see Fig. 2) of the smRLC (Espinoza-Fonseca 
et al. 2008). Therefore, combining in silico MD simula-
tions and pseudophosphorylation is a powerful technique 
for understanding basic structure–function relationship and 
also the mechanistic basis of disease-causing mutations of 
RLC. Pseudophosphorylation not only improves systolic 
function but also avoids adverse effects resulting from the 
D166V RLC mutation (Granzier and de Tombe 2015). In 
such pseudophosphorylation, the phospho-mimic negative 
charge is constitutive, which means that in vivo, the heart 
cannot control the charged-state of RLC and dynamically 
respond to altered demands.
Recently, it was found that in the beating heart, cRLC 
is constitutively and stably phosphorylated at a level of 
0.45 mol Pi/mol RLC due to a balance between cMLCK 
activity and MLCP (myosin light-chain phosphatase) activ-
ity (Chang et al. 2015). Thus, pseudophosphorylated RLC 
along with unphosphorylated RLC at in vivo ratios can be 
used for exchange into muscle fibers or myofibrils to test 
functional implication of RLC phosphorylation in normal 
and disease conditions, assuming that the D substitution 
is physiologically analogous to serine phosphorylation 
in vivo. The drawback of this S15D mutation approach 
is that it will not easily be adapted to patients. A possible 
alternative is the manipulation of the activities of either 
cMLCK (increasing it) or cMLCP (lowering it) (Granzier 
and de Tombe 2015). The reason is that these enzymes are 
highly specific toward cRLC, and therefore the technique 
may be feasible without adversely affecting effects on other 
proteins (Kamm and Stull 2011).
Direct phosphorylation
In addition to transgenic methods, RLC can be directly phos-
phorylated in vivo. For example, the hypertrophic agonist 
angiotensin II (AngII) plays an important role in regulat-
ing vascular tone as well as in maintaining systemic blood 
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pressure. Volatile anesthetics may inhibit AngII-induced 
vascular contraction via inhibiting RLC phosphorylation (Qi 
et al. 2009). Aoki et al. injected AngII and phenylephrine into 
the jugular vein of adult rats to promote phosphorylation of 
cRLC in the heart (Aoki et al. 2000). AngII and phenyle-
phrine increased the basal level of phosphorylated RLC by 
30 to 38 % and by 45 %, respectively. The increased RLC 
phosphorylation is caused by activation of the Ca2+/calmodu-
lin pathway activation and subsequent MLCK activation. This 
method induces the formation of well-organized sarcomeres 
in the cardiomyocytes. In other studies, mice were treated 
with β-adrenergic agonists like Isoproterenol (Isoprenaline), 
which induces cardiac hypertrophy in wild-type mice and is 
associated with an increase in MYL2v phosphorylation in 
mice that lack cMLCK, by activating the ZIP Kinase (Ding 
et al. 2010). A recent study infused AngII type 1 receptor 
(AT1R) biased ligand, namely TRV120023, into DCM mice 
for 15 min. The observed enhancement of cardiac contrac-
tility was associated with an increase in ventricular MYL2 
phosphorylation activated by the β-arrestin downstream sign-
aling pathway (Tarigopula et al. 2015). AT1R may prove to 
be a novel inotropic approach in familial DCM. Other ino-
tropic agents such as pimobendan and levosimendan probably 
inhibit phosphodiesterase, which may limit their use in DCM 
(Kass and Solaro 2006; Nonaka et al. 2015). These stud-
ies suggest that hypertrophic stimuli act upstream of cRLC 
phosphorylation. These pharmacological stimuli can be used 
to understand the function of cRLC phosphorylation in dis-
ease processes. The phosphorylation level achieved exceeds 
the physiological levels and thus may not reflect an in vivo 
mechanism. However, lowering doses of hypertrophic ago-
nists may achieve physiological levels of RLC phosphoryla-
tion. Agonist administration is invasive, so side effects need 
to be checked, such as compensatory over- or under-expres-
sion of other proteins and non-physiological phosphorylation 
of RLC or other proteins. RLC phosphorylation is manipu-
lated directly with agonists but the effects are difficult to con-
trol. Additionally, a study used 15-Hz tetanic stimulation in 
skMLCK knock-out mice, and found some RLC monophos-
phorylation (Zhi et al. 2005). However, it may be caused by 
redundancy between skMLCK and smMLCK, so this method 
is not widely used (Takashima 2009a).
Nevertheless, in vivo phosphorylation targets specific 
RLC isoforms, which allows exploration of phosphoryla-
tion effects in different muscle types under physiological 
conditions. Commonly used in vivo methods are summa-
rized in Table 2.
In vitro modification
In vitro modification of RLC phosphorylation levels is rela-
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In vitro methods include enzymatic, genetic, chemical, bio-
logical approaches, and direct physico-chemical methods.
Overview of kinase methods
Kinases used for in vitro modification of the phospho-
rylation state include MLCK, PAK, and Rho-kinase. The 
MLCK family is a set of calmodulin-dependent protein 
kinases which readily phosphorylate different RLCs. 
Smooth muscle MLCK (smMLCK) is expressed in most 
tissue including smooth muscle, skeletal muscle, and 
cardiac muscle. smMLCK catalyzes Ca2+/calmodulin-
dependent phosphorylation of RLC in epithelial, endothe-
lial, and other kinds of non-muscle cells. The smMLCK 
is sufficient for initiating smooth muscle contraction or 
actomyosin-dependent movement in non-muscle cells (Yu 
et al. 2010). Thus, the smooth muscle MLCK expressed by 
the MYLK gene is ubiquitous. In smooth muscle cells, the 
concentration of smMLCK and its substrate, RLC, is about 
4 μmol/l and 30–40 μmol/l, respectively (Takashima 
2009b). The skMLCK is a distinct kinase mainly found 
in skeletal muscle, particularly in fast-twitch fibers (Allen 
et al. 2008). Although it was reported in cardiac muscle, 
the amount is too low to maintain cardiac RLC phospho-
rylation (Davis et al. 2001) as demonstrated by knock-outs 
of skMLCK with no effect on cRLC phosphorylation (Zhi 
et al. 2005). The skMLCK is not selective, as it phospho-
rylates RLCs from smooth, skeletal, and cardiac muscles 
with similar maximal rate (Vmax) and Michaelis constant 
(Km) (Stull et al. 1986). Although skMLCK is activated by 
Ca2+ and the catalysis core recognizes the RLC binding 
site, the mechanism is different from that of smMLCK. 
Under steady-state conditions, skMLCK follows a rapid-
equilibrium random bi–bi reaction (two substrates con-
verted to two products) whereas smMLCK proceeds by 
an ordered sequential mechanism in which Mg-ATP binds 
first, followed by the RLC substrate (Bowman et al. 1992). 
cMLCK is a kinase first found in 2008 and only present 
in vertebrate cardiac ventricular and atrial myocytes (Chan 
et al. 2008). The cMLCK has a catalytic core domain and 
regulatory segment that are conserved in skMLCK. How-
ever, there is uncertainty about whether the cMLCK kinase 
ability to phosphorylate RLC is Ca2+/calmodulin depend-
ent or not. In rat cardiomyocytes, cMLCK phosphorylates 
RLC without Ca2+/calmodulin dependence in vitro (Chan 
et al. 2008). However, at around the same time, human 
cMLCK was found to be Ca2+/calmodulin dependent 
in vitro (Seguchi et al. 2007). Recently though, it has been 
shown in rat trabeculae that cMLCK indeed phosphoryl-
ates cRLC in a Ca2+/Calmodulin-dependent manner both 
in vitro and in situ (Kampourakis and Irving 2015). The 
phosphorylation efficiency was about 100 % (1 mol Pi/mol 
RLC) and the fact that in vivo multiple phosphorylated 
species of cRLC are present may be explained by the pres-
ence of different kinases for cRLC other than cMLCK in 
rodent heart (Chang et al. 2010; Jiang et al. 2014; Venema 
et al. 1993).
MLCKs have been used to phosphorylate RLC in mus-
cles from various species such as rabbit, mouse, rat, and 
Drosophila (Stull et al. 2011). MLCK is available commer-
cially. Alternatively, it can be recombinantly isolated and 
purified in the laboratory (Greenberg et al. 2009). Besides 
MLCK, other kinases such PAK are also widely used in 
RLC phosphorylation. A detail review will be given below.
Phosphorylation and de‑phosphorylation methodology 
targeting or using kinases
In vitro phosphorylation of cRLC is simply achieved by 
incubating 0.5 µM of MLCK with zipper-interacting kinase 
(ZIP kinase) dissolved in buffer (containing CaCl2, MgCl2, 
ATP, etc.) and incubated with 0.1–0.5 µM RLC for 0.5–2 h 
at 25–37 °C or at 4 °C overnight. This method yields almost 
100 % cRLC phosphorylation, i.e., the cRLC species are 
phosphorylated at Ser15 position with almost 100 % effi-
ciency (Toepfer et al. 2013). A higher concentration of 
MLCK may result in diphosphorylation. The ZIP Kinase is 
added along with cMLCK in order to increase RLC phos-
phorylation to the required level, since ZIP Kinase directly 
phosphorylates cRLC independently of MLCK pathway 
(Chang et al. 2015).
Using purified cMLCK catalytic domain along with 
Ca2+/calmodulin, ATPγS thiophosphorylates Ser15 of 
cRLC that was labeled by bifunctional sulforhodamine 
(BSR). ATPγS was used because thiophosphorylated pro-
teins are relatively resistant to dephosphorylation by con-
taminating or endogenous protein phosphatases in the 
muscle tissue samples (Gratecos and Fischer 1974). In this 
study (Kampourakis and Irving 2015), at a cMLCK:cRLC 
ratio of 1:500 or 1:200, almost 100 % of cRLC was mono-
phosphorylated. Thiophosphorylated cRLC was then 
exchanged into demembranated muscle fibers to visualize 
the orientation of myosin S1’s cRLC region in the acto-
myosin machinery using polarized fluorescence measure-
ments in resting, active, and rigor conditions. Although, 
only about 10–30 % exchange of the BSR-labeled thiophos-
phorylated cRLC was achieved, this may closely mimic the 
basal in vivo level of phosphorylated cRLC (40–50 %) in 
the contracting myocardium as was reported before (Her-
ring and England 1986; Silver et al. 1986). Exchange and 
incorporation of BSR-labeled thiophosphorylated cRLC 
had minimal effect in overall protein composition of the 
permeabilized tissue, only lowering the total amount of 
few proteins. Significantly though, exchange of the BSR-
thiophosphorylated cRLC caused lowering of the amount 
of phosphorylated TnI and phosphorylated MyBP-C.
792 Eur Biophys J (2016) 45:779–805
1 3
Recombinantly expressed RLC is dephosphoryl-
ated with shrimp alkaline phosphatase in vitro (Toepfer 
et al. 2013). MLCK inhibitors such as 50 µM of ML-9 
and 400 µM of nonapeptide rkkykyrrk-NH2 (D-PIK) are 
also used to reduce RLC phosphorylation in vitro (Feigh-
ery et al. 2008). Mixing specific ratios of phosphorylated 
and de-phosphorylated RLC prior to light-chain exchange 
into permeabilized cells effectively provides control of the 
phosphorylation. For example, in vivo conditions of RLC 
phosphorylation without tampering with the phosphoryla-
tion level of other sarcomeric proteins are achieved. The 
approach takes advantage of the fact that RLC is readily 
exchangeable in permeabilized muscle cells (Borejdo et al. 
2001; Caorsi et al. 2011; Toepfer et al. 2013). RLC dissoci-
ates spontaneously from the myosin heavy chain and dif-
fuses out of the filament lattice (Yang and Sweeney 1995). 
Addition of RLC to the bathing medium of RLC-extracted 
permeabilized muscle cells restores functional activity 
as measured by calcium-dependent force generation and 
relaxation and velocity-dependent force generation, indi-
cating that RLC effectively re-binds to its myosin target. 
RLC extraction of up to 80 % can be achieved, accompa-
nied by some extraction of myosin-binding protein C and 
of troponin components, principally TnC (Toepfer et al. 
2013). Inclusion of troponin and MyBP-C in the incuba-
tion medium improves the recovery of physiological func-
tion as these proteins also reversibly dissociate from the 
myofilament during RLC exchange and are replenished 
from the incubation medium. Moreover, as shown recently 
(Kampourakis and Irving 2015), either chemical permea-
bilization procedures using detergents (Triton X-100) or 
treatment of the tissue with solutions containing EGTA 
(ethylene glycol tetraacetic acid) or BDM (2,3-butanedi-
one monoxime) have no effect on the RLC phosphorylation 
level. The RLC exchange procedure in chemically perme-
abilized or demembranated muscle fibers or myofibrils is 
therefore convenient, and provides precise control of phos-
phorylation levels of RLC incorporated into the filament 
lattice. This avoids complications resulting from inadvert-
ent changes in the phosphorylation levels of other sarcom-
eric proteins, as would be the case if the kinases or phos-
phatases are added directly to the permeabilized cells. This 
method also has the advantage that RLC carrying muta-
tions or RLC that have been engineered to carry fluorescent 
reporters at specific sites can readily be introduced into the 
muscle fibres or myofibrils. However, in vitro phospho-
rylation may not mimic the in vivo MLCK activity as the 
kinases may target different sites depending on whether 
phosphorylation occurs in vivo or in vitro.
Reduction of phosphorylation is achieved using selec-
tive apoptotic agents targeting MLCK, as has been shown 
in smooth muscle cells (Fazal et al. 2005). Moreover, 
MLCK inhibitors such as 50 μM of ML-9 and 400 μM of 
nonapeptide rkkykyrrk-NH2 (D-PIK) are used to reduce 
RLC phosphorylation in vitro (Feighery et al. 2008). 
Another method for reducing RLC phosphorylation is by 
transfecting cultured cells with anti-sense MLCK, as used 
by Petrache et al. who found that caspase-dependent cleav-
age of MLCK was implicated in pulmonary endothelial 
cell apoptosis (Petrache et al. 2003). Caspase-mediated 
cleavage of MLCK as used in this study could potentially 
be used as another tool for inhibiting MLCK and reducing 
RLC phosphorylation in striated muscle in vitro. Inhibitory 
antibodies against MLCK to block RLC phosphorylation 
are used, but the effectiveness and reliability of this method 
depend on the specificity of the antibodies (Fazal et al. 
2005).
Other commonly used kinases for RLC phosphoryla-
tion are Rho-associated kinase (Rho-kinase) and protein 
kinase C (PKC). Rho-kinase is also involved in RLC phos-
phorylation in striated muscle. For example, adult rat ven-
tricular myocytes were treated with the Rho-kinase inhibi-
tor Y-27632 at a concentration of 10 µM so that it does not 
phosphorylate the myosin-binding phosphatase targeting 
subunit (MYPT), the catalytic subunit of protein phos-
phatase 1 (PP1) (Rajashree et al. 2005). This results in inhi-
bition of RLC phosphorylation. It used an antibody (12896, 
Santa Cruz) to target phosphor-Thr18 and Ser19, which are 
phosphorylation sites of smooth muscle and non-muscle 
cells. It should be verified by antibody that targets phos-
phor-Ser 15. However, this study still suggests an important 
role for α-adrenergic signaling in modulation of RLC phos-
phorylation via inhibition of the myosin phosphatase.
The phosphorylation pattern of cRLC by PKC is differ-
ent from that by MLCK (Scruggs and Solaro 2011) (Ven-
ema et al. 1993). In adult rat heart myofibrils in vitro, PKC 
mediated a phosphorylation of RLC with a stoichiometry 
(0.7 mol of phosphate/mol of protein) similar to that medi-
ated by MLCK (Venema et al. 1993).
Other kinases such as p21-activated kinase (PAK) and 
P34 kinase also affect RLC phosphorylation, but most 
reports refer to smooth muscle and non-muscle cells (Chu 
et al. 2013).
For example, γ-PAK, that is activated by GTP-binding 
proteins Cdc42 and Rac, catalyses phosphorylation of 
intact non-muscle myosin-II and isolated recombinant RLC 
(Chu et al. 2013). However, the PAK isoform of smooth 
muscle tissue, known as PAK1, affects RLC phosphoryla-
tion differently. By incubating guinea pig Triton-perme-
abilized smooth muscle tissue with active PAK1, it was 
found that PAK1 phosphorylates and inhibits smMLCK 
which reduces RLC phosphorylation. This, in turn, reduced 
the rate of smooth muscle contraction (Wirth et al. 2003). 
Purified P34 kinase (cyclin-p34cdc2) also phosphoryl-
ates RLC of cytoplasmic and smooth muscle myosin-II 
in vitro on Ser1 or Ser2 and Thr9 (Satterwhite et al. 1992). 
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The procedures for using these kinases are similar to that 
for MLCK: incubation of the kinase with myosin RLC for 
30 min at 4, 25, or 37 °C (depending on the type of RLC) 
achieves a high level of phosphorylation (Satterwhite et al. 
1992).
These in vitro smooth muscle strategies using various 
kinases can be applied to striated muscle by using the engi-
neered recombinant RLC and exchanged into muscle fibers 
or myofibrils.
Genetic engineering and pseudophosphorylation
Genetic engineering is used to explore RLC expression and 
phosphorylation (Koga and Ikebe 2008; Lossie et al. 2012). 
Using RNA interference (RNAi) to interfere Rho1 (Rho-
kinase) expression in Drosophila S2 cells, the role of Rho-
kinase-dependent RLC phosphorylation in the localization 
of myosin was examined (Dean and Spudich 2006). The 
use of RNAi is powerful and versatile. Whole genome-wide 
maps of promoter and enhancer sequences for all genes 
open the door to targeted and controlled genetic expres-
sion to study their effects and functions with the caveat of 
potential secondary over- or under-expression effects on 
other genes in the cell due to false targets stemming from 
similarity in gene sequences. The technique could be uti-
lized in cultured striated myocytes.
Pseudophosphorylation of RLC is another genetic 
approach to modulate phosphorylation. This technique is 
the same as discussed above, but is also used in vitro to 
engineer recombinant RLC. Pseudophosphorylated RLC is 
studied by in vitro biochemical techniques or is exchanged 
into muscle fibers (Muthu et al. 2014). (See above “In vivo 
modifications” section for details).
Chemical and biological factors
Chemical and biological factors inhibit myosin light chain 
phosphatase or activate phosphorylation of RLC via signal-
ing pathways. Yamakita performed in situ phosphorylation 
of smooth muscle and non-muscle RLC in dividing REF-
4A cells using [32p] orthophosphoric acid (Yamakita et al. 
1994). At a concentration of 1 U/ml, thrombin, which is a 
serine protease, induces a prolonged increase in the phos-
phorylation of RLC, reaching a peak after 1 min of expo-
sure to thrombin and maintaining elevated phosphorylation 
for at least 30 min (Amerongen et al. 1998; Richardson 
et al. 2000). These strategies can also be used in striated 
muscle cells to modulate RLC phosphorylation levels. For 
instance, myofibrils from rabbit psoas muscle are dephos-
phorylated completely by incubation in glycerinating 
solution containing 4 mM ATP incubating for 60 min at 
24 °C. Subsequently, phosphorylated muscle is prepared by 
inhibiting the activity of phosphatase with the addition of 
20 mM NaF and in the presence of 20 mM phosphate along 
with 5 mM ATP (Stewart et al. 2010).
Chemical genetic approach
Genetic or a pharmacological approaches alone (discussed 
above) have several disadvantages, especially when tar-
geting a specific kinase to modulate RLC or other sarco-
meric protein phosphorylation. Since the ATP-binding 
sites of kinases are highly conserved, it is difficult to target 
kinases specifically using pharmacological inhibitors. On 
the other hand, genetic approaches to deactivate kinases 
are very specific but take time to be effective and levels of 
inactivation are difficult to control. Small molecule phar-
macological inhibitors inactivate kinases rapidly and in a 
dose-dependent manner. Moreover, interpretation of results 
using genetic or pharmacological techniques is complicated 
by functional redundancy of kinases and the overlapping 
substrates of multiple kinases. To overcome this, Kevan 
Shokat and his colleagues (Garske et al. 2011) developed a 
chemical genetic approach. A mutation is created to change 
a conserved hydrophobic amino acid acting as a gate-
keeper in the active site of kinases to a small amino acid 
such as alanine or glycine to generate a uniquely targeta-
ble mutant kinase. This mutated kinase can then be targeted 
with chemically bulky analogs of natural kinase inhibi-
tors to occupy the new enlarged pocket of the gatekeeper 
site, whereas wild-type kinases will not be inhibited. The 
effectiveness of the method depends on a mutation that 
retains kinase activity, which is not achieved in ~30 % of 
cases. Moreover, non-covalent inhibitor binding limits the 
power of this method. An alternate method which does not 
involve bulky amino acid substitution is the engineering of 
a cysteine gatekeeper in the active site that can be inhibited 
with an electrophilic inhibitor. The advantage of a cysteine 
gatekeeper is that it is rare in the kinome and is inherently 
hydrophobic in nature as well. This strategy achieves speci-
ficity via shape complementarity.
This chemical genetic approach has been exploited to 
identify RLC as a direct substrate for phosphorylation by 
ZIP kinase to regulate smooth muscle contraction (Moffat 
et al. 2011). A ZIP-L93G mutant kinase was created that 
is capable of utilizing a bulky analog of ATP (P32 labeled 
6-phenyl-ATP) as substrate. Using SDS-PAGE and auto-
radiography, RLC was found to be the direct substrate of 
ZIP kinase in situ. Thus, this approach manipulates RLC 
phosphorylation in different tissue systems by selectively 
inhibiting kinases.
Physico‑chemical methods
Physico-chemical methods involve the use of physical 
perturbation such as microinjection, stretch, and protein 
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exchange to incorporate proteins or factors in vitro to mod-
ulate RLC phosphorylation. These methods are used in 
striated muscle and non-muscle cells. Zeng et al. used two 
physical methods to modify phosphorylation of RLC (Zeng 
et al. 2000). The first method was microinjection of PAK2 
into endothelial cells which increased the phosphorylated 
RLC from 0.2 mol PO4/mol to 0.37 mol PO4/mol RLC 
in 35 min. Moreover, the reaction was specific for mono-
phosphorylation of RLC but not for di-phosphorylation. 
The second method was by constitutively delivering active 
PAK2 into bovine pulmonary artery endothelial cytosol by 
using the osmotic delivery method developed by Okada 
and Rechsteiner (1982).
Toepfer et al. exchanged native RLC with recombinant 
RLC phosphorylated in vitro by MLCK and ZIP-kinase 
into permeabilized trabeculae of the rat heart using the 
technique developed in Irving and Goldman laboratories 
(Colson et al. 2010; Toepfer et al. 2013). Trabecular mus-
cle was incubated in three sequential 15-min incubations 
at 20 °C with fresh 0.5 mg/ml RLC exchange solution 
incorporating 0.5 mg/ml TnC, to reintroduce TnC that is 
lost during exchange so as not to alter contractile charac-
teristics of the preparations (Borejdo et al. 2001). Tem-
perature is important for the exchange method because 
higher temperature causes higher tension, which may 
damage the muscle. Albeit, in Toepfer et al., exchange 
was done in the presence of 5 mM MgATP and without 
calcium (relaxing condition), thus technically no active 
tension was developed in the muscle fiber. This technique 
increases the RLC phosphorylation level by about 40 % at 
20 °C. The physical exchange method benefits from the 
ability to introduce fluorescent dyes at specific sites in 
the recombinant RLC at the same time. The fluorescence 
signal is helpful to track the extent of exchange. The 
exchange method can also be applied to ELC (Ushakov 
et al. 2011), but suitable, reversible conditions are more 
difficult to establish.
Stretch stimuli on muscle cells have been shown to mod-
ulate RLC phosphorylation levels in smooth muscle. In the 
canine basilar artery, stretch increases smooth muscle RLC 
tri-phosphorylation at MLCK and PKC sites (Nakayama 
et al. 2003) indicating that stretch could regulate kinase 
activity. PKCα and PP2A (Protein phosphatase 2A) have 
physical and functional connection in smooth muscle cells 
(Azzi et al. 1998). A muscle pre-load stimulus achieved by 
stretching rabbit ventricular myocardium under physiologi-
cal condition increases phosphorylation of RLC and other 
important sarcomeric components including tropomyosin 
and TnI (Monasky et al. 2010). This suggests that stretch-
ing intact muscle fibers modulates RLC phosphorylation 
physiologically. However, stretching alone is not specific 
and can cause biochemical alteration to various proteins in 
the sarcomere, not just RLC.
Applying isotropic compressive stress or shrinkage 
using a silicone chamber on murine C2C12 skeletal myo-
blast cells dephosphorylates RLC via. RhoA phosphoryla-
tion by adenylyl cyclase/PKA (protein kinase A) pathway 
(Takemoto et al. 2015). Studies on adult striated muscle 
fibers are needed to reveal the role of mechano-sensation 
induced by stretch or compressive stress on the extent of 
RLC phosphorylation.
RLC phosphorylation is also correlated with the fre-
quency of stimulation for cardiac muscle contraction (Dias 
et al. 2006; Silver et al. 1986). These studies reported that 
increasing stimulation frequency from 0 to 126 beats/min 
for 30 min produced a frequency-dependent increase in 
RLC phosphorylation from 0.1 to 0.4 mol Pi/mol RLC in 
perfused rabbit ventricular septae. Thus, frequency of stim-
ulation modulates RLC phosphorylation in situ.
RLC phosphorylation is also correlated with temperature 
(Moore et al. 1990). Phosphorylation of RLC decreases 
with increasing incubation temperature of mammalian skel-
etal muscle fiber.
Commonly used in vitro RLC phosphorylation methods 
are compared and summarized in Table 3.
Biomechanical measurements after RLC 
manipulation
The functional effects of in vitro or in vivo manipulations 
of RLC phosphorylation need precise evaluation in a physi-
ological setting that mimics the live tissue environment. 
In an ex vivo setting, measurement of the force response 
and the ATPase rate of the muscle fiber or the myofibril 
are needed. Single-filament biophysical experiments such 
as in vitro motility assays (Karabina et al. 2015), or spin-
labeling combined with TIRF microscopy (Burghardt and 
Sikkink 2013) or laser-trap assays (Previs et al. 2014) 
provide important information at the molecular level, but 
single filament or studies of solubilized proteins lack the 
thick–thin filament sarcomeric lattice structure and suffer 
from the inability to measure a force response. Moreover, 
these experiments are not conducive to mimic the contrac-
tion cycle of cardiac beating by stretching or releasing per 
se. Chemically demembranated single muscle fibers or iso-
lated single myofibrils offer ex vivo physiological systems 
in which RLC is readily exchanged (Borejdo et al. 2001; 
Caorsi et al. 2011) with controlled levels of phospho-
rylation. Permeabilized muscle fibers mounted between a 
force transducer and a piezo-motor or moving coil motor 
and are exposed to solutions to activate, relax, or put the 
fibers into rigor. Contraction of muscle fibers is activated 
by addition of calcium or by temperature-jump (T-jump), 
or by laser flash photolysis of NPE-caged ATP. The force 
response is measured directly using the force transducer, 
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whereas actomyosin ATPase of the muscle is measured 
using a fluorescent phosphate sensor added to the bathing 
solution that rapidly binds phosphate after ATP breakdown. 
This provides measurement with millisecond time resolu-
tion. Stretch–release protocols explore the effect of force 
and ATPase before, during, or after stretch of muscle fibers 
to understand the effect of RLC phosphorylation in cardiac 
muscle during the heart beat cycle, or when using stretch-
release protocols in skeletal muscle as experienced during 
eccentric exercise such as jumping or sprinting (Bickham 
et al. 2011; He et al. 2000, 1997; Mansfield et al. 2012; 
Toepfer et al. 2013). Measurement of force exhibited by 
single myofibrils is measurable by taking advantage of 
myofibril adherence to clean glass needles with one of the 
needle attached to a piezomotor to stretch or release the 
myofibril. The other microneedle bends under the force 
produced by the myofibril. The microneedle bending is 
detected from the moving shadow of the needle, illumi-
nated by a HeNe laser, which is cast onto a double photodi-
ode connected differentially. Thus the needle acts as a force 
transducer to report force generation by the myofibril. The 
myofibril is activated and relaxed using calcium-containing 
or calcium-free solution, respectively, by switching the 
laminar flow of solution flowing over the myofibril from a 
double-barreled pipette. The type of solution in which the 
myofibril is bathed depends on the position of the double-
barreled pipette (Song et al. 2013; Tesi et al. 2000, 2002; 
Vikhorev et al. 2014). Recombinant RLC exchange into 
myofibril to control phosphorylation and subsequent force 
responses under different conditions can be measured.
Step changes in length or force and ATPase rate meas-
urements are routinely used to investigate the mechanical 
transduction process in muscle. Sinusoidal small ampli-
tude length perturbation of the muscle fiber or myofibril 
over a range of frequencies has also been used to retrieve 
information on acto-myosin cross-bridge attachment-
detachment rates and muscle passive properties (Iorga et al. 
2012; Miller et al. 2013). These techniques combined with 
exchange of RLC with manipulated phosphorylation can 
further help us understand the role of RLC phosphorylation 
in muscle contraction.
Techniques to determine the site(s) and extent 
of RLC phosphorylation
The measurement of in vivo RLC phosphorylation is still 
quite a challenge, as evidenced by the reported phospho-
rylation ratio of skRLC ranging from 5–40 % (Takashima 
2009a). Considering the ubiquitous phosphatase activity 
in tissue, it is important to inhibit phosphatase when pre-
paring sample for phosphorylation analysis. Methods to 
detect phosphorylation site(s) in normal and diseased tissue 
samples and for the measurement of the extent of phospho-
rylation are improving in terms of sensitivity, precision, 
and throughput. Some of the major approaches in phos-
phoproteomic analyses are protein mixture fractionation by 
gel electrophoresis, liquid chromatography, in tandem with 
phosphopeptide enrichment techniques coupled to mass 
spectrometry (MS) characterization.
In gel-based approaches, conventional two-dimensional 
electrophoresis (2DE) gel analysis is most common to 
detect phosphovariants of proteins according to their iso-
electric point by isoelectric focusing and subsequently by 
molecular weight via SDS-PAGE (O’Farrell 1975). Phos-
phoproteins and their variants that have been separated 
by both charge and weight are visualized after staining 
(Steinberg 2009). For example, autoradiography using 
32P/33P labeling of phosphate groups is possibly the most 
sensitive, albeit time-consuming, method. Immunoblot-
ting using phospho-specific antibodies is extensively used 
to detect phospho-Tyr in proteins. The disadvantage is the 
low abundance of phospho-Tyr species, which makes them 
hard to detect, and phospho-Ser/Thr antibodies are known 
to have low specificity. Immunoblotting is performed using 
antibodies against RLC. Some RLC antibodies are specific 
for certain RLCs, i.e., cRLC and not smRLC, or specific 
for the animal type, i.e., human or mouse or rat. However, 
others are promiscuous, as the amino acid sequence they 
recognize is conserved across RLC types (Fig. 2).
Fluorescent stains specific for phosphoproteins are 
used in 1DE and 2DE gels. Pro-Q Diamond (Molecular 
Probes®) selectively stain phosphoproteins in acrylamide 
gels, without the need for blotting or phosphoprotein-spe-
cific antibodies and Western-blot analysis (Schulenberg 
et al. 2004; Steinberg 2009). Pro-Q stain is not quantitative, 
but can be used quantitatively if aided by sensitive mass 
spectrometry. Another technique uses a phosphate-binding 
tag (Phos-Tag), which binds specifically to phosphoryl-
ated ions and thus has a sensitivity to phosphoproteins that 
is similar to autoradiography. Phos-tag functions at neutral 
pH for the visualization of phosphorylated proteins in 1DE 
and 2DE gels (Kinoshita et al. 2006). Using Phos-tag gels, 
Marston and other groups found different phosphovariants 
of RLC in cardiac muscle tissues from normal and diseased 
states (Kinoshita et al. 2009; Toepfer et al. 2013). Moreo-
ver, Phos-tag SDS-PAGE can be used to clearly distinguish 
between thiophosphorylated and phosphorylated RLC as 
thiophosphorylated RLC migrates faster (Sutherland and 
Walsh 2012).
The 2DE gel system detects phosphorylation variants 
and phosphorylation sites (amount and location) as it can 
be conjugated with protease digestion and tandem mass 
spectrometry (also known as MS/MS) (Lin et al. 2010). 
For detection of very low phosphorylation levels in protein 
samples, phosphorylation enrichment of the sample is used 
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before MS/MS detection. Analyses and detail descriptions 
can be found in the review by Dunn et al. (2010). Other 
than gel-based approaches, liquid chromatography along 
with MS gives sensitive separation and detection of phos-
phoproteins and phosphorylated sites. Affinity enrichment 
strategies such as immunoprecipitation and immune-affin-
ity chromatography are used for purification of phospho-
proteins followed by peptide fragmentation and MS/MS 
or tandem mass spectrometry to detect phosphorylation 
sites. The small molecular weight of RLCs and their acidic 
nature due to phosphorylation means that the species sepa-
rate well in 2DE isoelectric focusing (IEF) gels, using tube 
gel electrophoresis with ampholytes of narrow pH range 
(4.5–5.4 pH range). The use of tube gels allows a com-
paratively large amount (~1 mg) of myofilament-enriched 
homogenate to be loaded, which permits the detection of 
low levels of phosphorylation or other post-translational 
modifications by MS or other methods (Westwood and 
Perry 1981). Analysis of the gel reveals variants based on 
their phosphorylation states: un-phosphorylated, mono-
phosphorylated, and di-phosphorylated. This technique has 
been used to examine the phosphorylation of RLC in rab-
bit, rat, and mouse (Frearson et al. 1976).
The caveat of the 2DE system is that it is time consum-
ing. A faster alternative is the 1DE Urea-Glycerol PAGE 
that has been extensively used for separating RLC spe-
cies, especially from cardiac muscle tissue samples (Craig 
et al. 1987; Sobieszek 1986; Szczesna et al. 2002). Add-
ing SDS and performing Urea/SDS-PAGE for cardiac sam-
ples has also been used for separating RLC phosphovari-
ants (Kerrick et al. 2009; Muthu et al. 2012). This 1DE gel 
approach can be combined with western blot analysis by 
means of antibodies specific to the phosphorylated form of 
RLC (Davis et al. 2001). Moreover, these procedures are 
facilitated by selective extraction of RLC from the muscle 
homogenate before electrophoretic separation as described 
in the work of Davis et al. (Davis et al. 2001).
Discussion and perspectives
In vivo manipulation
Studying the function of RLC phosphorylation in vivo is 
a major advantage of transgenic techniques, to investigate 
the effect of phosphorylation from the molecular to the 
whole organism levels. Transgenic techniques may also 
allow studies of specific diseases in animal models. How-
ever, creating transgenic animals is time-consuming and 
their maintenance is expensive. A mutation introduced in 
the live animals may have resulted in the development of 
secondary unidentified changes which might compensate 
or accentuate the effects of the mutation, complicating the 
interpretation of the results. Also, the penetrance of the 
mutation may be variable and tissue specific (Cooper et al. 
2013; Pereira et al. 1994).
Limiting expression levels using RNAi or transgenic 
targeting techniques may cause false positives because 
of interactions with multiple genes and isoforms of RLC 
or MLCK. For example, gene duplication and conversion 
events of mammalian RLC genes from smooth muscle, 
and non-muscle cells, lead to a high degree of sequence 
similarity and consequent difficulties for specific RNAi 
targeting or transgenesis. With regard to compensatory 
expression or modification of other proteins in cells carry-
ing mutant constructs in transgenic animals, Scruggs et al. 
found that transgenically abolishing RLC phosphorylation 
reduces phosphorylation of both myosin binding protein C 
(MyBP-C) and TnI in cardiac muscle (Scruggs et al. 2009). 
These modifications could mask or amplify the effect of the 
original mutation. Minamisawa et al. demonstrated that a 
post-transcriptional compensatory program is triggered to 
maintain normal expression levels and functions even in 
a heterozygous mouse with a single dosage of ventricular 
RLC gene (Minamisawa et al. 1999).
Another disadvantage of the transgenic approach is the 
positional effect of the transgene. Depending on the land-
ing location of the transgene in the genome, expression of 
other genes along with the transgene can be affected. In 
spite of these possible side effects, various protein–protein, 
biochemical, and chemo-mechanical interactions in the 
muscle and non-muscle tissues are deciphered by in vivo 
transgenics (Maughan et al. 2005). More recently, advanced 
technologies such as the phiC31 recombinase systems and 
the CRISPR/Cas9 system allow precise in vivo mutations 
or transgenesis in both invertebrates and vertebrates and 
have the potential to heal by gene therapy (Bischof et al. 
2007; High et al. 2014; Imayoshi et al. 2013; Wang et al. 
2013). These advances in in vivo genetic technologies will 
allow more precise in vivo targeting of RLC phosphoryla-
tion with regard to specific sites or specific chromosomal 
locations, or the targeting of specific kinases, which may 
open the possibility of therapeutic interventions.
In vivo pharmacological treatments are attractive 
approaches due to their simplicity. However, as Scruggs 
et al. found, abolishing RLC phosphorylation affects phos-
phorylation of both MyBP-C and TnI (Scruggs et al. 2009), 
and general administration of compounds such as AngII 
(Aoki et al. 2000) may have multiple effects that compli-
cate experimental results and interpretations. In vivo pro-
pranolol injection in mice was initially used to dephos-
phorylate reported TnI in cardiac muscle (Vikhorev et al. 
2014). The authors found the TnI phosphorylation was 
successfully reduced from 1.0 to 0.3 mol Pi/mol TnI and 
was accompanied with a reduction in the phosphorylation 
level of MyBP-C from 2.9 to 0.25 mol Pi/mol MyBP-C, but 
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has no effect on RLC phosphorylation (Chang et al. 2015). 
Thus, since RLC phosphorylation modulation could affect 
MyBP-C and TnI phosphorylation, propranolol treatment 
could be used as a negative control to change MyBP-C and 
TnI phosphorylation without affecting RLC phosphoryla-
tion. Although this approach depends on the level of pro-
tein dephosphorylation, it may establish the direct physio-
logical and pharmacological effect of RLC phosphorylation 
on its own.
In vitro manipulations
Phosphorylation of RLC using an in vitro approach is faster 
than in vivo for studying mechanisms and for finding thera-
peutic targets or strategies to ameliorate muscle diseases. 
Targeting kinases like MLCK, and Rho-kinase, that are 
directly associated with RLC phosphorylation regulation 
is effective. The caveat in this approach is the assumption 
that the kinase acts on physiological in vivo target sites 
with similar effectiveness as in vitro, which might not be 
the case. Moreover, some recombinant kinases might have 
low specificity depending on the tissue origin or if they are 
bacteriologically expressed. Also, some kinases may have a 
broad functional spectrum. Therefore, optimization of the 
in vitro conditions to mimic the physiological environment 
as much as possible is needed. False positives or negatives 
might arise in genetic engineering, when using chemical/
biological agents such as calyculin A, or when applying 
chemical genetic approaches or physical methods. Never-
theless, due to their ease and speed, the in vitro techniques 
have definite advantages over in vivo approaches.
The molecular players maintaining RLC 
phosphorylation/dephosphorylation balance
Physiologically RLC phosphorylation in striated or smooth 
muscle is regulated by the balance of activities between 
MLCK and the myosin light chain phosphatase (MLCP). 
There are several molecular players that control this 
dynamic process. Along with regulation via MLCK activ-
ity (reviewed above), MLCP also keeps the activity balance 
(for detailed review see (Hartshorne et al. 2004). The major 
functional subunit of MLCP is the myosin phosphatase tar-
geting protein 1 (MYPT1) in smooth muscle, and MYPT2 
in skeletal and cardiac muscle. MLCP inhibition is regu-
lated by agonist stimulation via various G protein-coupled 
receptors and RhoA and Rho-kinase pathways (Hartshorne 
et al. 1998; Somlyo and Somlyo 2003), mostly targeting 
the MYPT1 or MYPT2. An additional kinase that phospho-
rylates and inhibits MLCP is known as MPT1 kinase (Bor-
man et al. 2002). Activation of MLCP is usually related to 
the increase in the levels of cAMP and cGMP dependent on 
the activity of protein kinase A/G (PKA and PKG). MLCP 
activation is known to be fulfilled by PKA/PKG phospho-
rylation of the MYPT1 in smooth muscle (Nakamura et al. 
2007; Somlyo 2007) that opposes the inactivating RhoA/
Rho-kinase pathway.
Recently, a novel regulator named myosin phosphatase-
Rho interacting protein (M-RIP) was identified in smooth 
muscle (Gebbink et al. 1997; Surks et al. 2003). M-RIP is 
a member of the MLCP complex, which associates with 
the myosin phosphatase targeting protein 1 (MYPT1), the 
regulatory- and myosin-binding subunit of MLCP. M-RIP 
directly binds to both RhoA and MLCP at adjacent sites 
to form the trimer. By binding to actin via the N-terminus, 
M-RIP links MLCP to the sarcomeric filaments to dephos-
phorylate RLC (Mulder et al. 2005). However, most of 
the studies explored smooth muscle cells and non-mus-
cle cells (Riddick et al. 2008; Surks et al. 2005). Besides 
RNAi, another method described by Mahavadi et al. uses 
PKG to regulate phosphorylation (Mahavadi et al. 2014). 
It was found that PKG-induced phosphorylation of M-RIP 
enhances its association with MYPT1 to increase MLCP 
activity and RLC dephosphorylation. Thus, M-RIP is a tar-
get of PKG to mediate RLC dephosphorylation and smooth 
muscle relaxation. M-RIP is thus a potential target for 
modulating RLC phosphorylation in smooth muscle and 
possibly also in striated muscle.
In striated muscle too, MLCP activity balances the 
MLCK activity. It has been shown that RLC phosphoryla-
tion in fast twitch skeletal muscle fibers is slower than the 
twitch contraction but is faster than RLC dephosphoryla-
tion by MLCP (Sweeney et al. 1993). However, in cardiac 
muscle the rates of RLC phosphorylation and dephospho-
rylation are lower than in skeletal muscle, suggesting that 
this balancing activity is tissue specific and important for 
modulation of muscle contraction (Sweeney et al. 1993).
Issues and future directions
The role of striated muscle RLC phosphorylation in health 
and disease is an emerging question. The quest for under-
standing the mechanism by which RLC phosphoryla-
tion affects muscle function may lead to the development 
of therapeutic targets. Some of the major issues that need 
addressing are:
1. How does RLC phosphorylation affect the acto–myo-
sin interactions, the structure of the myosin cross-
bridge and the ability of the muscle to generate force?
2. What are the molecular mechanisms by which natu-
rally occurring mutations change RLC phosphorylation 
levels?
3. How do changes in RLC phosphorylation affect the 
phosphoproteome of the muscle cells, and how do 
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these changes in phosphoproteome affect cellular 
behavior and the contractile machinery?
4. Do therapeutic modifications of the RLC phosphoryla-
tion level improve contractile performance in disease 
conditions?
5. What are the in vivo drivers that control RLC phos-
phorylation? Are these specific to RLC or shared with 
other proteins? How dynamic are the phosphorylation 
changes, and on what time scale do they operate?
To answer the above questions, a number of technologies 
will need to be applied, singly and in combination. Opti-
cal and electron microscopy may reveal structural changes 
brought about by changes in phosphorylation. Low-angle 
X-ray crystallography and FRET (Förster resonance energy 
transfer) studies may be used to observe the dynamics of 
cross-bridge interactions in different phosphorylation states 
of RLC. These studies may focus on the structure of the 
cross-bridges, but also in the inter-filament spacing and 
myofibrillar organization. Pseudophosphorylation may pro-
vide stable systems to aid structural studies and molecular 
dynamic simulations. Results will assist the elaboration of 
models of contraction in which the contractile performance 
and efficiency of muscle is related to disease states encoun-
tered in hypertrophic or dilated cardiomyopathies.
Conclusions
RLC phosphorylation regulates muscle contraction and 
other cellular functions, with important consequences for 
muscle behavior in health and disease. RLC phosphoryla-
tion plays a part in muscle disorders and may be a future 
therapeutic target. This review summarizes the structure 
and function of RLC and gives an overview of the meth-
ods available for manipulating and testing the effect of 
RLC phosphorylation in muscle tissue, focusing on striated 
muscle. We also compare the advantages and disadvantages 
of in vivo and in vitro methods and suggest their potential 
applications.
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